Comparison · NCT02469857-513b0406
AB103 0.5 mg/kg vs Placebo: Number of Patients With One or More Secondary Infections
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. AB103 0.5 mg/kg vs Placebo: Number of Patients With One or More Secondary Infections. Trial comparisons, record NCT02469857-513b0406. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02469857-513b0406
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.21 | 0.151 | 0.284 | wilson | |
| Risk in group 2 | 0.218 | 0.159 | 0.291 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0079 | -0.102 | 0.0867 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.964 | 0.62 | 1.5 | log | |
| Odds ratio, group 1 over group 2 | 0.954 | 0.544 | 1.67 | log | |
| Number needed to treat, for one fewer participant with the outcome on AB103 0.5 mg/kg than on Placebo | 127 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | AB103 0.5 mg/kg | AB103 0.5 mg/kg, IV infusion, single dose | 30 | 143 | OG000 |
| Group 2 | Placebo | NaCl 0.9%, IV infusion, single dose | 32 | 147 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With One or More Secondary Infections
- Description
- Number of Patients with One or More Secondary Infections During the Study
- Time frame
- 28 days
- Population
- As Treated/Safety Analysis Population: all randomized patients who were exposed to study drug (active or placebo) and categorized according to the treatment actually received.
Source ClinicalTrials.gov
Trial
- Title
- Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
- NCT number
- NCT02469857
- Phases
- PHASE3
- Conditions
- Necrotizing Soft Tissue Infections, Necrotizing Fasciitis, Fournier's Gangrene
- Interventions
- AB103 0.5 mg/kg, NaCl 0.9%
- Lead sponsor
- Atox Bio Ltd
- Results first posted
- 2021-10-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02469857?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02469857-513b0406